Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/63823
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA
Author: Bartley, P.
Ross, D.
Latham, S.
Martin-Harris, M.
Budgen, B.
Wilczek, V.
Branford, S.
Hughes, T.
Morley, A.
Citation: International Journal of Laboratory Hematology (Print Edition), 2010; 32(6 Part 1):E222-E228
Publisher: Blackwell Publishing Ltd
Issue Date: 2010
ISSN: 1751-5521
1751-553X
Statement of
Responsibility: 
P. A. Bartley, D. M. Ross, S. Latham, M. H. Martin-Harris, B. Budgen, V. Wilczek, S. Branford, T. P. Hughes, A. A. Morley
Abstract: Increasing numbers of patients with chronic myeloid leukaemia (CML) treated with tyrosine kinase inhibitors achieve undetectable levels of BCR-ABL mRNA using sensitive quantitative real-time reverse transcriptase PCR (RT-qPCR) methods and a method to measure minimal residual disease (MRD) in patients with low levels could be of value. Following isolation and sequencing of the patient-specific BCR-ABL breakpoint, a DNA-based nested qPCR assay was established, and MRD was measured by this method and one-round RT-qPCR in 38 samples from 24 patients with CML. Mixing experiments using patient DNA in normal DNA indicated that DNA qPCR could detect BCR-ABL sequences at a limit of approximately 10⁻⁶. In 22 samples in which MRD was detectable by both methods, comparison of the results of DNA qPCR with the results obtained on the same sample by RT-qPCR showed good correlation. In another 16 samples, BCR-ABL mRNA was not detectable by RT-qPCR. In 8 of the 16 samples, BCR-ABL DNA was detected at levels ranging from 1.1 × 10⁻⁵ up to 2.8 × 10⁻⁴ and in the remaining eight samples BCR-ABL was not detected by either method. In one patient, who had stopped imatinib, an almost 1000-fold rise in MRD, to 5.2 × 10⁻⁴ was observed in sequential samples. Nested DNA qPCR was more sensitive than one-round RT-qPCR and could be used for the monitoring of patients with CML with very low levels of MRD.
Keywords: Minimal residual disease; chronic myeloid leukaemia; BCR-ABL; PCR; monitoring
Rights: © 2010 Blackwell Publishing Ltd.
RMID: 0020101187
DOI: 10.1111/j.1751-553X.2010.01236.x
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.